| Chidamide Bridging for CAR-T Therapy (NCT05370547) | Chinese PLA General Hospital | 2022-05-25 |
| Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy (NCT05349266) | Zhejiang University | 2022-03-18 |
| CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases (NCT04662294) | Zhejiang University | 2021-11-18 |
| 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma (NCT05096234) | Stanford University | 2021-09-28 |
| Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study (NCT05191225) | Laida Cuevas Palomares | 2021-09-28 |
| Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05206071) | Hebei Senlang Biotechnology Inc., Ltd. | 2021-05-01 |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies (NCT04796675) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-04-10 |
| A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies (NCT04532203) | Zhejiang University | 2020-11-01 |
| Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT04586478) | Juventas Cell Therapy Ltd. | 2020-10-26 |
| A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma (NCT04666168) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-10-22 |
| Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04447547) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-06-30 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma (NCT04156828) | University of Washington | 2020-03-31 |
| A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy (NCT04226989) | He Huang | 2020-02-05 |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04155840) | University of Washington | 2020-01-31 |
| CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (NCT03765177) | Ottawa Hospital Research Institute | 2019-10-16 |
| γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (NCT04028440) | Institute of Hematology & Blood Diseases Hospital, China | 2019-10-01 |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma (NCT03789240) | National Cancer Institute (NCI) | 2019-08-22 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (NCT04002947) | National Cancer Institute (NCI) | 2019-08-05 |
| Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NCT03974243) | Chipscreen Biosciences, Ltd. | 2019-07-11 |
| Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies (NCT03955783) | Sanjay Mohan | 2019-06-21 |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas (NCT03893682) | Aptose Biosciences Inc. | 2019-04-30 |
| Vaccination With Flt3L, Radiation, and Poly-ICLC (NCT03789097) | Icahn School of Medicine at Mount Sinai | 2019-04-05 |
| A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT03797261) | AbbVie | 2019-03-18 |
| Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma (NCT04497688) | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 2019-01-01 |
| MB-CART20.1 Lymphoma (NCT03664635) | Miltenyi Biomedicine GmbH | 2018-09-25 |
| A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients (NCT04152148) | Bio-Thera Solutions | 2018-09-04 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (NCT03527147) | Acerta Pharma BV | 2018-06-19 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (NCT03198026) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-02-20 |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (NCT03236857) | AbbVie | 2017-11-08 |
| Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (NCT03317899) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-10-12 |
| A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NCT02961881) | Amgen | 2017-09-18 |
| Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing (NCT03226704) | National Cancer Institute (NCI) | 2017-08-14 |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas (NCT03188965) | Bayer | 2017-07-06 |
| Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma (NCT03074825) | Chipscreen Biosciences, Ltd. | 2017-05-09 |
| Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma (NCT03456466) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-05-01 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma (NCT03075696) | Hoffmann-La Roche | 2017-02-21 |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer (NCT03027284) | Eli Lilly and Company | 2017-02-03 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome (NCT02848274) | Stanford University | 2016-10-01 |
| A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma (NCT02919670) | Dana-Farber Cancer Institute | 2016-10-01 |
| A Study of Mitoxantrone Hydrochloride Liposome Infusion (NCT02856685) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2016-08-01 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02611323) | Hoffmann-La Roche | 2016-03-09 |
| Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation (NCT02719821) | University of Wisconsin, Madison | 2016-03-01 |
| A Study of PLX51107 in Advanced Malignancies (NCT02683395) | Plexxikon | 2016-03-01 |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma (NCT02722733) | Maria Sklodowska-Curie National Research Institute of Oncology | 2016-03-01 |
| A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants (NCT02624986) | Hoffmann-La Roche | 2015-12-23 |
| Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 (NCT02507336) | University of Miami | 2015-11-24 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (NCT02356159) | National Cancer Institute (NCI) | 2015-09-24 |
| A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT02453087) | Hoffmann-La Roche | 2015-08-04 |
| Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) (NCT02408042) | Western Regional Medical Center | 2015-04-01 |
| GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant (NCT02360111) | Memorial Sloan Kettering Cancer Center | 2015-02-01 |
| Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies (NCT02315118) | National University Hospital, Singapore | 2014-12-01 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant (NCT01930162) | Novartis Pharmaceuticals | 2014-10-07 |
| CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (NCT02259556) | Chinese PLA General Hospital | 2014-10-01 |
| Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting (NCT02199288) | Hoffmann-La Roche | 2014-08-01 |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma (NCT02059239) | Weill Medical College of Cornell University | 2014-06-04 |
| Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (NCT02050347) | Baylor College of Medicine | 2014-04-01 |
| A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 (NCT01969682) | AbbVie | 2014-04-01 |
| A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma (NCT02078102) | Sherif S. Farag | 2014-03-11 |
| Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation (NCT02087657) | University of Kansas Medical Center | 2014-03-01 |
| Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma (NCT02697552) | HUYABIO International, LLC. | 2014-03-01 |
| An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma (NCT01969695) | AbbVie | 2013-12-20 |
| Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies (NCT02006485) | TG Therapeutics, Inc. | 2013-12-13 |
| Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma (NCT01980654) | Pharmacyclics LLC. | 2013-12-01 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (NCT02007811) | University of Erlangen-Nürnberg Medical School | 2013-11-01 |
| Meloxicam vs Placebo for Mobilization (NCT02003625) | Massachusetts General Hospital | 2013-10-01 |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant (NCT01904175) | Duke University | 2013-08-01 |
| P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies (NCT01854567) | Mesoblast, Ltd. | 2013-08-01 |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor (NCT01696461) | Center for International Blood and Marrow Transplant Research | 2013-05-01 |
| Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation (NCT01767714) | Sanofi | 2013-04-01 |
| High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (NCT01840566) | Memorial Sloan Kettering Cancer Center | 2013-04-01 |
| Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn (NCT01789723) | Acrotech Biopharma Inc. | 2013-03-01 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (NCT01728207) | Gilead Sciences | 2013-03-01 |
| Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (NCT01597219) | University College, London | 2013-03-01 |
| Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma (NCT01768338) | Michael John Robertson | 2013-02-01 |
| Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (NCT01555892) | Baylor College of Medicine | 2013-01-14 |
| Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT01767766) | TG Therapeutics, Inc. | 2013-01-07 |
| Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma (NCT01755975) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (NCT01746849) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies (NCT01745913) | Weill Medical College of Cornell University | 2012-10-26 |
| An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma (NCT01684865) | Hoffmann-La Roche | 2012-10-22 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease (NCT01458288) | GPCR Therapeutics, Inc. | 2012-10-01 |
| Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant (NCT01699581) | Greg Monohan | 2012-09-01 |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (NCT01592370) | Bristol-Myers Squibb | 2012-08-02 |
| Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (NCT01585688) | Gilead Sciences | 2012-08-01 |
| A Study of LY3023414 in Participants With Advanced Cancer (NCT01655225) | Eli Lilly and Company | 2012-07-31 |
| Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (NCT01610180) | Fondazione Progetto Ematologia | 2012-06-01 |
| A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT01594229) | AbbVie | 2012-05-21 |
| Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies (NCT01643603) | Barbara Ann Karmanos Cancer Institute | 2012-05-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (NCT01532635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-03-01 |
| Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT (NCT01598558) | Sanjiv Sam Gambhir | 2012-01-01 |
| A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab (NCT01461928) | Hoffmann-La Roche | 2011-12-20 |
| Reduced Intensity Double Umbilical Cord Blood Transplantation (NCT01408563) | Massachusetts General Hospital | 2011-12-01 |
| Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide (NCT01458366) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-11-09 |
| IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma (NCT01491841) | Anne Beaven, MD | 2011-11-01 |
| Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (NCT01452334) | Bristol-Myers Squibb | 2011-11-01 |